|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1750 Yankee Doodle Road |
Address2 | N179 |
| City | Eagan |
State | MN |
Zip Code | 55121 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 5687-12
|
||||||||
|
6. House ID# 324990000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Lin M Nelson |
Date | 10/18/2024 4:15:07 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Prescription Drug Affordability
S775 Increasing Transparency in Generic Drug Application
to provide for increased transparency in generic drug application
Sen Hassan, Margaret Wood (D-NH)
HR9070, Affordable Prescriptions for Patients Act of 2024
to amend title 35, United States Code, to prohibit product hopping, and for other purposes
Sen. Cornyn, John (R-TX)
Insulin Out of Pocket Charges; Finance PBNM Framework Proposals; Covid Vaccines
S. 150 - Affordable Prescriptions for Patients Act of 2023
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. John Cornyn (R-TX)
S. 127 - Pharmacy Benefit Manager Transparency Act of 2023
A bill to prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
Sponsor: Sen. Maria Cantwell (D-WA)
S.1067 - Ensuring Timely Access to Generics Act of 2023
To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S.1114 - Expanding Access to Low-Cost Generics Act of 2023
To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
Sponsor: Sen. Smith, Tina [D-MN]
S.1269 - INSULIN Act of 2023
To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Sponsor: Sen. Shaheen, Jeanne [D-NH]
S.1339 - Pharmacy Benefit Manager Reform Act
To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
Sponsor: Sen. Sanders, Bernard [I-VT]
S.2305 - Biosimilar Red Tape Elimination Act
To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Sponsor: Sen. Lee, Mike [R-UT]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lin |
Nelson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
APTC Affordability; Affordable Care Act;
ACA Subsidies and tax credits, Mental health care, hospital billing, Transparency in coverage, Hospital consolidation, Health Equity index, cybersecurity, provider directories, artificial intelligence, health equity, healthcare fraud, food as medicine, Mental health parity
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lin |
Nelson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
APTC
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
telehealth parity Provider Directories; Medicaid Redeterminations; Draft Duals legislation; Same-day billing restrictions in Medicaid; IRA copay smoothing; Medicare Advantage Health Equity Index
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lin |
Nelson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues
Generics access; Cell & Gene therapy; Step Therapy
Bills
H.R.7312 - EPCS 2.0 Act
To provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage.
Sponsor: Rep. Kuster, Ann M. [D-NH-2]
S.2666 - EPCS 2.0 Act
To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage.
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
S. 1114, Expanding Access to Low-Cost Generics Act
To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period.
Sponsor: Sen. Smith, Tina [D-MN] "
S.1339 - Pharmacy Benefit Manager Reform Act
To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage.
Sponsor: Sen. Sanders, Bernard [I-VT]
S. 150 - Affordable Prescriptions for Patients Act of 2023
To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Sponsor: Sen. Cornyn, John [R-TX]
S. 2305 - Biosimilar Red Tape Elimination Act
To improve the requirements for making a determination of interchangeability of a biological product and its reference product.
Sponsor: Sen. Lee, Mike [R-UT]
S. 127 - Pharmacy Benefit Manager Transparency Act of 2023
To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes.
Sponsor: Sen. Cantwell, Maria [D-WA]
H.R. 6094 - PROTECT Rare Act
To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition, and for other purposes.
Sponsor: Rep. Matsui, Doris O. [D-CA-7]
S. 148 - Stop STALLING Act
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Sponsor: Sen. Amy Klobuchar (D-MN)
S. 142 - Preserve Access to Affordable Generics and Biosimilars Act
A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.
Sponsor: Sen. Amy Klobuchar (D-MN)
S.1542, DRUG Act
To improve services provided by pharmacy benefit managers.
Sponsor: Sen. Marshall, Roger [R-KS]
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lin |
Nelson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |